Abcam, ab251531, Anti-8-methyladenosine (m8A) antibody [EPR-20836-125-1] - BSA and Azide free

Size: 100µg / 1mg
Rabbit Recombinant Monoclonal 8-methyladenosine (m8A) antibody. Carrier free. Suitable for ELISA, IP and reacts with Modified Nucleic Acid samples.
Key facts
Host species:Rabbit,
Clonality:Monoclonal,
Clone number:EPR-20836-125-1,
Isotype:IgG,
Carrier free:Yes,
Applications:IP, ELISASee reactivity dataSee the reactivity data table below for information on validated species and application combinations.,
Immunogen:The exact immunogen used to generate this antibody is proprietary information.,
Specificity:Has been developed to discriminate between the modified base 8-methyladenosine (m8A) and the unmodified counterpart Adenosine (A).

Product details:
ab251531 is the carrier-free version of
ab211498
Patented technology
Our RabMAb
technology is a patented hybridoma-based technology for making rabbit monoclonal antibodies. For details on our patents, please refer to
RabMAb® patents
What are the advantages of a recombinant monoclonal antibody?
This product is a recombinant monoclonal antibody, which offers several advantages including:
- High batch-to-batch consistency and reproducibility
- Improved sensitivity and specificity
- Long-term security of supply
- Animal-free batch production
For more information, read more on
recombinant antibodies
Conjugation ready
Our carrier-free antibodies are typically supplied in a PBS-only formulation, purified and free of BSA, sodium azide and glycerol. This conjugation-ready format is designed for use with fluorochromes, metal isotopes, oligonucleotides, and enzymes, which makes them ideal for antibody labelling, functional and cell-based assays, flow-based assays (e.g. mass cytometry) and Multiplex Imaging applications.
Use our
conjugation kits
for antibody conjugates that are ready-to-use in as little as 20 minutes with 1 minute hands-on-time and 100% antibody recovery: available for fluorescent dyes, HRP, biotin and gold.
Compatibility
This product is compatible with the Maxpar
Antibody Labeling Kit from Fluidigm, without the need for antibody preparation. Maxpar
is a trademark of Fluidigm Canada Inc.

Properties and Storage Information:
Form-Liquid, Storage buffer-pH: 7.2 - 7.4Constituents: PBS, Shipped at conditions-Blue Ice, Appropriate short-term storage conditions-+4°C, Appropriate long-term storage conditions-+4°C, Storage information-Do Not Freeze

Supplementary Information:
This supplementary information is collated from multiple sources and compiled automatically.
8-Methyladenosine (m8A) represents a modified nucleoside with a methyl group added to the adenosine molecule. It is known also as N-methyladenosine. The mass of m8A depends on its position within a nucleic acid sequence; generally the addition of a methyl group alters its properties without significantly affecting its overall mass. This modification typically occurs within rRNA tRNA and mRNA across many species including humans. The expression of m8A is predominantly associated with cellular RNA but detailed characterization of its distribution within particular tissues or cell types remains an active research area.
Biological function summary
8-methyladenosine modifies RNA and affects various cellular processes. Its presence can influence RNA stability translation efficiency and splicing patterns. Although not part of any known stable complex it cooperates with proteins involved in RNA metabolism such as methyltransferases which mediate its methylation. The dynamic modification of m8A implies a regulatory role in RNA-related processes impacting the cell's ability to respond to different physiological demands.
Pathways
M8A modification integrates into cellular regulatory systems including the RNA processing and decay pathways. It connects with proteins such as methyltransferases which are responsible for adding methyl groups to nucleosides. In RNA processing pathways m8A potentially affects the interactions between RNA and RNA-binding proteins influencing RNA localization and degradation. Its role interplays with the m6A methylation pathway sharing some common methyltransferases and demethylases that adjust methylation marks on RNA.
M8A alteration associates with cancer and neurodegenerative diseases. Abnormal m8A levels may disrupt normal RNA metabolism and contribute to tumorigenesis or cancer progression. Within neurodegenerative diseases m8A modifications in RNA could affect neuronal function and survival linking to proteins involved in RNA transport and degradation. Research efforts continue to uncover how this RNA modification might serve as a biomarker or therapeutic target in various pathological conditions.